

AACR Bulletin Board

Institution of Page Charges

Effective January 1, 1998, a page charge of \$50 per printed page will be levied on all manuscripts published in *Clinical Cancer Research*. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no other source of grant or other support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

1999 Annual Meeting

The AACR's Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in Philadelphia, PA, April 10-14, 1999. The Chairperson of the Annual Meeting is Wau Ki Hong of the UT-M.D. Anderson Cancer Center. Co-Chairpersons are Carol W. Greider, Johns Hopkins University School of Medicine; Joseph F. Fraumeni, Jr., National Cancer Institute; and Leroy Fong Liu, Robert Wood Johnson Medical School.

The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, scientific forums, and meet-the-expert sunrise sessions. It will also review proffered papers submitted by members of the cancer research community and will schedule acceptable ones in minisymposia, poster discussion sessions, and poster sessions. The deadline for submission of abstracts will be **November 6, 1998**. Further program information can be found on the AACR's Website (<http://www.aacr.org>).

Call for Nominations for 1999 AACR-Pezcoller International Award for Cancer Research

The AACR-Pezcoller International Award for Cancer Research is given annually to a scientist who has made a major scientific discovery in the field of cancer. The Pezcoller Foundation was established in 1982 by Professor Alessio Pezcoller, a dedicated Italian surgeon who has made important contributions to medicine during his career and who, through his foresight, vision, and generous gift in support of the formation of the Foundation, stimulated others to make significant advances in cancer research. Over the past decade the Pezcoller Foundation has given a major award for outstanding contributions to cancer and cancer-related biomedical science.

The American Association for Cancer Research (AACR) was founded in 1907 by eleven physicians and scientists dedicated to the conquest of cancer and now has over 13,000 members in more than 60 countries who are experts in basic, clinical, and translational cancer research. The AACR fulfills its mission, the communication of important scientific results, in a variety of forums including publications, meetings, and training and educational programs. Because of their joint commitment to scientific excellence in cancer research, the Foundation and the AACR have now agreed to collaborate on the presentation of this award. This will strengthen their already well-established relationship and facilitate international collaborations and interactions. Due to the successful implementation of this joint program in 1998, the Foundation and the AACR have agreed to give this award on an annual basis.

The awardee will be selected by an international committee of AACR members appointed by the AACR President with the agreement of the Council of the Pezcoller Foundation. Although normally the Award will be presented to a single investigator, in exceptional cases two individuals may be selected to share the award when their investigations have resulted in related prizeworthy work. The committee will make its selection solely on the basis of the awardee's scientific accomplishments without regard to race, gender, nationality, or religious or political views. The candidate will give an award lecture during the AACR Annual Meeting in Philadelphia, PA, USA (April 10-14, 1999) and will receive the award in a ceremony at the Foundation's headquarters in Trento, Italy, right after the AACR Annual Meeting. The award consists of an honorarium and a commemorative plaque.

The Foundation and the AACR are now soliciting nominations for the 1999 Award. Nominations can be made by any scientist who is now or has been affiliated with an institution engaged in cancer research. Institutions or organizations are not eligible for this award, and candidates may not nominate themselves.

AACR

The American Association for Cancer Research (AACR) was founded in 1907 to bring together active investigators of the cancer problem for the presentation and discussion of new findings and to foster advances in cancer research. Today the Association has 13,000 members working in all of the subdivisions of cancer research in the United States, Canada, and more than 60 other countries. Information on AACR programs and activities can be obtained from

**American Association for
Cancer Research
Public Ledger Building
150 South Independence Mall West
Suite 826
Philadelphia, PA 19106-3483
Phone: (215) 440-9300
Fax: (215) 440-9313
E-mail: aacr@aacr.org**

The AACR welcomes applications for membership from the readership. Scientists engaged in all areas of cancer research are eligible for membership. There are three categories of membership: *active membership*, open to cancer researchers working in the Americas; *corresponding membership*, to those working outside the Americas; and *associate membership*, to graduate and medical students, postdoctoral fellows, and physicians-in-training. Further information on the qualifications for each category as well as the benefits of membership can be found on the application forms at the back of this issue.

There is no official application form for this award. The nomination package should consist of the following:

- the candidate's curriculum vitae;
- an indication of the most important references in the candidate's curriculum vitae and list of publications;
- a letter of recommendation in English (500 words, maximum) describing the candidate's major scientific achievements and explaining the impact of these achievements on progress in cancer research.

Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination.

The deadline for receipt of nominations by the AACR is **October 1, 1998**, for consideration for the 1999 Award. Questions about the nomination process should be directed to the AACR Office via FAX at (215) 440-9313 or E-mail at aacr@aacr.org. Nominators should submit the original plus 12 copies of their nominations to: AACR-Pezcoller International Award for Cancer Research c/o American Association for Cancer Research, Inc.

Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483, USA

Call for Nominations for AACR Awards

The AACR presents six awards to distinguished scientists at its Annual Meeting. The Awards Committee, consisting of six separate subsections, will recommend candidates for each award to the AACR Executive Committee. Following is a description of each award. Members wishing to make nominations should provide a short description of the candidate's accomplishments; the subcommittee involved will obtain further documentation on suitable candidates. Nominations may be directed to the Association Office for forwarding to the appropriate subcommittee. This material should be received no later than **September 1, 1998**.

Clowes Memorial Award. The Eli Lilly Company established the Clowes Memorial Lecture to honor Dr. G. H. A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly, the purpose of the award is to give "recognition of outstanding research accomplished in some recent period." The Clowes Award should recognize outstanding recent accomplishments in basic cancer research, and the Board of Directors construes this to mean both laboratory research and epidemiological investigations.

Joseph H. Burchenal AACR Clinical Research Award. Bristol-Myers Squibb has established this award to recognize outstanding achievements in clinical cancer research. It is named for Dr. Joseph H. Burchenal, past president and honorary member of the AACR and a leading figure in the field of cancer chemotherapy. There

are no restrictions on the age or geographic location of the awardee.

Richard and Hinda Rosenthal Foundation Award. The Rosenthal Foundation has established this award to "recognize research which has made or gives the promise of soon making a notable contribution to improved clinical care in the field of cancer." The Foundation wishes to honor and provide incentive to young investigators relatively early in their careers. It has, therefore, stipulated that the Association restrict the award to individuals who are engaged in the practice of medicine, who reside in the Americas, and who will not be more than 50 years of age at the time of the award (April 1999).

Rhoads Memorial Award. In 1979, an anonymous donor established this award in memory of Dr. Cornelius P. Rhoads, a founder and the first Director of the Sloan-Kettering Institute for Cancer Research. This annual award is intended to give recognition to an "individual on the basis of meritorious achievement in cancer research." In accordance with the donor's wishes, the awardee must be a young investigator; therefore, the Board of Directors of the Association has stipulated that the recipient must not have reached his or her 41st birthday by the time of the award (April 1999).

Cain Memorial Award. The Warner-Lambert Company instituted this award to honor the memory of Dr. Bruce F. Cain of New Zealand for his work in the "design, synthesis, and biological evaluation of potential anticancer drugs." The purpose of the award is to "give recognition to an individual or research team for outstanding preclinical research that has implications for the improved care of cancer patients." Examples of such research include discovery of a significant new anticancer agent and major contributions to a compound's application as an antitumor agent. The award will recognize outstanding contributions in the fields of medicinal chemistry, biochemistry, or tumor biology as related to drug discovery; will encompass anticancer, antiviral, and antifungal agents; will have no age limit; and will be international in scope.

American Cancer Society Award. The American Cancer Society sponsors this award to honor outstanding achievements in the fields of epidemiology, biomarkers, and prevention. There are no age or geographical restrictions on the awardee.

AACR Special Conferences in Cancer Research

A number of meetings are now being organized in the AACR's series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Non-members may receive this information by sending their names and addresses to: Meetings Mailing List, AACR, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR's website (<http://www.aacr.org/confnc.tml>).

October 14-18, 1998

Gene Regulation and Cancer
(10th Anniversary of AACR Special Conferences in Cancer Research)

Chairpersons:

PHILLIP A. SHARP, Cambridge, MA
JACQUELINE A. LEES, Cambridge, MA
STEVEN L. MCKNIGHT, Dallas, TX
The Homestead, Hot Springs, VA

December 2-6, 1998

New Research Approaches to the Prevention and Cure of Prostate Cancer

Co-Chairpersons:

JONATHAN W. SIMONS, Baltimore, MD
KENNETH J. PIENTA, Ann Arbor, MI
Hyatt Grand Champions Resort, Indian Wells
(Palm Springs), CA

March 1999

Molecular Determinants of Sensitivity to Antitumor Agents

Co-Chairpersons:

MICHAEL B. KASTAN, Baltimore, MD
I. DAVID GOLDMAN, Bronx, NY
Location To Be Announced

AUTHOR INDEX

June 1998

- Abe, S., 1483
 Akagi, K., 1527
 Akiyoshi, T., 1507
 Alberti, D., 1429
 Alvarez, C. J., 1393
 Amenta, P. S., 1393
 Amiot, M., 1521
 Andrulis, I., 1451
 Antman, K. H., 1443
 Aoki, T., 1527
 Arzooonian, R., 1429
 Ayash, L. J., 1443

 Bansal, S., 1533
 Barillé, S., 1521
 Barnard, G. F., 1507
 Barnett, P. A., 1549
 Barr, L. F., 1557
 Bataille, R., 1521
 Bennett, W. P., 1499
 Bigner, D. D., 1415
 Blackstein, M., 1451
 Bodin, F., 1563
 Boiko, I. V., 1383
 Boku, N., 1469
 Borkowski, A., 1499
 Brünner, N., 1511
 Budnick, R. M., 1543
 Bullock, N., 1415
 Burris, H. A., 1459

 Campbell, S. E., 1557
 Caporaso, N. E., 1499
 Caron, P. C., 1421
 Carrat, F., 1375
 Casero, R. A., Jr., 1557
 Chastre, E., 1375
 Cheng, A. L., 1429
 Chin, K., 1469
 Christensen, I. J., 1511
 Chun, R., 1567
 Church, D., 1429
 Cimerman, N., 1511
 Clark, G. M., 1489
 Coleman, N., 1443
 Comoglio, P., 1375
 Cooley, A. J., 1567

 DeBloom, J. R., II, 1543
 Dexter, D. W., 1533
 Diamandis, E. P., 1489
 DiGioia, Y., 1375
 Dubois, I., 1359
 Dumont, L., 1421
 Dumontet, C., 1563

 Eckardt, J. R., 1459
 Eckhardt, S. G., 1459
 El-Deiry, W. S., 1499
 Elias, A. D., 1443

 Fleming, M. V., 1499
 Franssen, E., 1451
 Fraser, R-A., 1451
 Freedman, A. N., 1499
 Frei, E., III, 1443
 Friedman, A., 1415

 Friedman, H. S., 1415
 Fuchs, H., 1415
 Fujiwara, Y., 1527
 Fukuda, Y., 1475

 Ganapathi, R., 1459
 Garrett, L. D., 1567
 Geles, K. G., 1533
 Gespach, C., 1375
 Gill, G. M., 1437
 Goldstein, L. J., 1533
 Goss, P. E., 1451
 Gotoh, M., 1527
 Guinee, D. G., Jr., 1499

 Hait, W. N., 1393
 Hale, L. P., 1415
 Hammond, L. A., 1459
 Harada, M., 1475
 Haraguchi, M., 1507
 Harousseau, J-L., 1521
 Harris, C. C., 1499
 Hasebe, T., 1469
 Hawkins, M. J., 1437
 Hedley, D., 1451
 Higaki, N., 1527
 Hill, W., 1451
 Hirsch, A., 1359
 Hittelman, W. N., 1383
 Hodges, S., 1459
 Holm, B., 1367
 Hosokawa, K., 1469
 Hu, W., 1383
 Hutson, P. R., 1429

 Ibrahim, J., 1443
 Isikawa, M., 1475
 Izumi, K., 1475

 Jaunakais, D., 1437
 Jago, G., 1521
 Jensen, P. B., 1367
 Jett, J. R., 1499
 Johnson, S. P., 1415
 Johnston, P. G., 1469
 Jones, R. T., 1499

 Kaku, T., 1517
 Kamura, T., 1517
 Kates, R., 1451
 Kehrl, N., 1429
 Knight, S., 1451
 Kondo, H., 1469
 Kos, J., 1511
 Kotelevets, L., 1375
 Krašovec, M., 1511
 Kroll, R. A., 1549
 Kuhn, J. G., 1459

 Lee, S. E., 1415
 Leighton, J. C., 1533
 Levesque, M. A., 1489
 Li, J., 1415
 Liotta, L. A., 1499
 Liu, X-P., 1405
 Loewen, G. R., 1437
 Lubin, R., 1359

 Malpica, A., 1383
 Marnocha, R., 1429
 Marshall, J. L., 1437
 Mathevet, P., 1383
 McCauley, M., 1443
 McCormick, C. I., 1549
 McLendon, R., 1415
 Mellerin, M-P., 1521
 Michal, Y., 1563
 Midthun, D., 1499
 Milas, M., 1573
 Milleron, B., 1359
 Mills, L., 1443
 Mimori, K., 1507
 Mise, K., 1475
 Mitchell, M. F., 1383
 Miyake, H., 1475
 Modrich, P., 1415
 Monden, M., 1527
 Mori, M., 1507
 Mukai, K., 1469
 Myers, D. E., 1405
 Myers, R., 1451
 Myint, M. A., 1533

 Nakamori, S., 1527
 Nakano, H., 1517
 Nakashima, M., 1517
 Narla, R. K., 1405
 Ness, E., 1437
 Neuwelt, E. A., 1549
 Nielsen, H-J., 1511
 Nishisho, I., 1527
 Nordlinger, B., 1375

 Obradovich, J. E., 1567
 Ohtsu, A., 1469
 Ohzato, H., 1527
 Oldfield, S., 1451
 Oshima, S., 1527

 Pairolero, P. C., 1499
 Pandey, D. K., 1383
 Pellat-Deceunynck, C., 1521
 Pineau, D., 1521
 Pollock, R. E., 1573
 Pomplun, M., 1429
 Porte, H., 1375
 Prévot, S., 1375
 Pritchard, K. I., 1451
 Puthier, D., 1521

 Rago, R., 1429
 Rapp, M-J., 1521
 Reddy, R. K., 1533
 Remsen, L. G., 1549
 Rizvi, N. A., 1437
 Robillard, N., 1521
 Roche, K., 1451
 Rodriguez, G. A., 1459
 Rogakto, A., 1533
 Rothenberg, M. L., 1459
 Rowinsky, E. K., 1459
 Rush, W. L., 1499

 Saito, D., 1469
 Saito, H., 1469

 Sakon, M., 1527
 Sano, N., 1475
 Scheinberg, D. A., 1421
 Schlichtholz, B., 1359
 Schnipper, L., 1443
 Schwartz, G., 1443
 Sehested, M., 1367
 Seki, S., 1469
 Sexton, G., 1549
 Shibusa, T., 1483
 Shijubo, N., 1483
 Shimada, Y., 1469
 Shiraishi, T., 1507
 Shirao, K., 1469
 Sonoda, K., 1517
 Soussi, T., 1359
 Stephens, R. W., 1511
 Stewart, C. C., 1543
 Stomper, P. C., 1543
 Sugimoto, K., 1527
 Sullivan, G. F., 1393
 Sun, D., 1573

 Tajiri, H., 1469
 Tamez, P., 1557
 Tashiro, S., 1475
 Tazelaar, H. D., 1499
 Teicher, B. A., 1443
 Thamm, D. H., 1567
 Trastek, V., 1499
 Travis, W. D., 1499
 Trédaniel, J., 1359
 Triboulet, J. P., 1375
 Trudeau, M., 1451
 Truglia, J. A., 1437
 Tutsch, K. D., 1429

 Uckun, F. M., 1405
 Ueo, H., 1507
 Ulm, E. H., 1437
 Urban, T., 1359

 Vail, D. M., 1567
 Villanueva, J. D., 1393
 Von Hoff, D. D., 1459

 Wada, D., 1475
 Warner, E., 1451
 Warr, D., 1451
 Warren, D., 1443
 Watanabe, T., 1517
 Webster, S., 1451
 Weiss, G. R., 1459
 Welsh, J. A., 1499
 Wheeler, C., 1443
 Wilding, G., 1429
 Wurtz, A., 1375

 Yamada, T., 1527
 Yamao, T., 1469
 Yang, J-M., 1393
 Yoe, J., 1437
 Yogita, S., 1475
 Yoshida, S., 1469
 Yu, D., 1573
 Yu, H., 1489

 Zalcman, G., 1359

Instructions for Authors

Scope

Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. *Clinical Cancer Research* is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in *Clinical Cancer Research*, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferny-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the *Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education* issued by the New York Academy of Sciences' Ad Hoc Committee on Animal Research, a copy of which is available for \$5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator's Institutional Review Board.

Review Process

The review process is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Publication Fees

A page charge of \$50 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Procedures for Submission

Submit papers directly to the Deputy Editor or to one of the seven Senior Editors, each of whom is responsible for a particular area of research. The Deputy Editor and the Senior Editors will conduct the review process with the expert assistance of the journal's Associate Editors, will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief, Deputy Editor, and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. **For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.**

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in *Clinical Cancer Research* that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;
9. Figures.

References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

SAMPLE REFERENCES:

1. Shaffer, D. W., Smith, L. S., Burris, H. A., Clark, G. M., Eckardt, J. R., Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn, J. G., and Von Hoff, D. D. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. *Cancer Res.*, 53: 5929-5933, 1993.
2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal antibody therapy of cancer. In: H. M. Pinedo, B. A. Chabner, and D. L. Longo (eds.), *Cancer Chemotherapy and Biological Response Modifiers Annual*, Vol. 11, pp. 177-203. Amsterdam: Elsevier Science Publishers B.V., 1990.

Figures

Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is \$975 per color figure. Submit color figures on flexible backing.

Proofs

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. **Proofs not received by the deadline will be published without the authors' corrections.** Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

Typesetting Manuscripts from Computer Disks

Clinical Cancer Research requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

Research Areas of the Editor-in-Chief, Deputy Editor, and Senior Editors

John Mendelsohn, M.D., Editor-in-Chief
Department of Educational Publishing Services-227
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6014; Fax: (713) 792-6016
E-mail: jmendelsohn@notes.mdacc.tmc.edu

Growth factors, hormones, cell growth; radiation therapy, surgery, subspecialty investigation

Waun Ki Hong, M.D., Deputy Editor
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Box 80
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6363; Fax: (713) 796-8655
E-mail: waun_hong@isqm.mda.uth.tmc.edu

Clinical trials targeted at specific malignancies, chemoprevention

Bruce A. Chabner, M.D.
Department of Hematology/Oncology
Massachusetts General Hospital
Cox Building, Room 640
100 Blossom Street

Boston, MA 02114
Phone: (617) 724-3200; Fax: (617) 724-3166
E-mail: chabner.bruce@mgh.harvard.edu

Clinical pharmacology and pharmacokinetics, drug metabolism, drug sensitivity and resistance, drug interactions

Michael B. Kastan, M.D., Ph.D.
Division of Pharmacology and Experimental Therapeutics
Johns Hopkins Hospital, Ross 345
720 Rutland Avenue
Baltimore, MD 21205
Phone: (410) 614-2747; Fax: (410) 614-4095
E-mail: mbkastan@welchlink.welch.jhu.edu

Cell cycle regulation, cell death

Lance A. Liotta, M.D., Ph.D.
Laboratory of Pathology
National Cancer Institute
Building 10, Room 2A33
National Institutes of Health
10 Center Drive, MSC 1500
Bethesda, MD 20892-1500
Phone: (301) 496-3185; Fax: (301) 402-0043
E-mail: lance@helix.nih.gov

Pathology, metastasis

David Sidransky, M.D.
Otolaryngology/Head & Neck Cancer Research
Johns Hopkins University
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
Phone: (410) 550-5153; Fax: (410) 614-1411
E-mail: dsidrans@welchlink.welch.jhu.edu

Molecular pathogenesis, molecular correlates

Paul Sondel, M.D., Ph.D.
Departments of Pediatrics, Human Oncology, & Genetics
University of Wisconsin Clinical Science Center
K4/448
600 Highland Avenue
Madison, WI 53792
Phone: (608) 263-9069; Fax: (608) 263-4226
E-mail: pmsondel@facstaff.wisc.edu

Immunotherapy and cytokines—preclinical, and clinical trials

Beverly A. Teicher, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center, DC 0540
Indianapolis, IN 46285
Phone: (317) 276-2739; Fax: (317) 277-3652
E-mail: teicher-beverly_a@lilly.com

Experimental therapeutics, preclinical pharmacology, combined modality regimens, animal therapy models

Jeffrey M. Trent, Ph.D.
Laboratory of Cancer Genetics
National Center for Human Genome Research
National Institutes of Health
Building 49, Room 4A22
49 Convent Drive, MSC 4470
Bethesda, MD 20892-4470
Phone: (301) 402-2023; Fax: (301) 402-2040
E-mail: jtrent@nchgr.nih.gov

Genetics, cytogenetics

For more information, contact:

John Mendelsohn, M.D., Editor-in-Chief, *Clinical Cancer Research*, Department of Educational Publishing Services-227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6014; Fax: (713) 792-6016

or:

Publications Department, American Association for Cancer Research, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Phone: (215) 440-9300; Fax: (215) 440-9355.

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Endogenous Sources of Mutations



November 11-15, 1998
Sanibel Harbour Resort and Spa
Ft. Myers, Florida

CONFERENCE CHAIRPERSONS

Lawrence J. Marnett / Nashville, TN
James A. Swenberg / Chapel Hill, NC
Tomas Lindahl / London, England

TENTATIVE SCIENTIFIC PROGRAM

Mutation Patterns

Jeffrey H. Miller / Los Angeles, CA

Endogenous DNA Damage

Miral Dizdaroglu / Gaithersburg, MD
Lawrence J. Marnett / Nashville, TN
James A. Swenberg / Chapel Hill, NC
David E. G. Shuker / Leicester, England
Nancy L. Oleinick / Cleveland, OH
Gerd P. Pfeifer / Duarte, CA
Erling Seeberg / Oslo, Norway

Repair

Arthur P. Grollman / Stony Brook, NY
Susan S. Wallace / Burlington, VT
Bruce Demple / Boston, MA
Leona D. Samson / Boston, MA
Tomas Lindahl / London, England
Joyce T. Reardon / Chapel Hill, NC
Malgorzata Zdzienicka / Leiden, The Netherlands

Susceptibility Factors in Endogenous Mutations

Thomas A. Kunkel / Research Triangle Park, NC
Christopher W. Lawrence / Rochester, NY
Mark Meuth / Salt Lake City, UT
Penny A. Jeggo / Falmer, England

Significance of Endogenous Mutations

Lawrence A. Loeb / Seattle, WA
Mutsuo Sekiguchi / Fukuoka, Japan
Steven R. Tannenbaum / Cambridge, MA

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for poster presentation. Selected proffered papers will also be scheduled for oral presentations.

Application deadline: August 28, 1998

Information and Application Forms

American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
e-mail: meetings@aacr.org
AACR Website: <http://www.aacr.org>

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Gene Regulation and Cancer

10th Anniversary of the AACR Special Conferences



October 14-18, 1998
The Homestead
Hot Springs, VA

CONFERENCE CO-CHAIRPERSONS

Phillip A. Sharp / Cambridge, MA
Jacqueline A. Lees / Cambridge, MA
Steven L. McKnight / Dallas, TX

CONFERENCE PROGRAM

Keynote Address

Leland H. Hartwell / Seattle, WA

Control of Cell Division and Gene Expression

Jacqueline A. Lees / Cambridge, MA
Scott W. Lowe / Cold Spring Harbor, NY
Nikola P. Pavletich / New York, NY

Mechanisms of Transcriptional Regulation

Jerry L. Workman / University Park, PA
Marian Carlson / New York, NY
David H. Price / Iowa City, IA

Growth Control and Chromatin Acetylation

C. David Allis / Rochester, NY
Kevin Struhl / Boston, MA
Robert N. Eisenman / Seattle, WA
Michael Grunstein / Los Angeles, CA

Regulation of Cell Death

Albert S. Baldwin / Chapel Hill, NC
Craig B. Thompson / Chicago, IL

Developmental Biology and Gene Regulation

Beverly M. Emerson / La Jolla, CA
Katia Georgopoulos / Cambridge, MA
Frank G. Grosveld / Rotterdam, The Netherlands

Signal to Transcription

Steven L. McKnight / Dallas, TX
David J. Mangelsdorf / Dallas, TX
Gregg L. Semenza / Baltimore, MD

Gene Expression Technology

Stephen H. Friend / Seattle, WA

Additional Speakers to be Announced

Application Deadline: July 31, 1998

Information and Application Forms:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: meetings@aacr.org
Website: <http://www.aacr.org>



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 13,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. subscriptions to the Association's high-quality journals *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates;
3. an advance copy of the Program and *Proceedings of the American Association for Cancer Research* that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. reduced registration rates at annual meetings;
5. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
6. substantially reduced registration rates for Special Conferences;
7. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
8. receipt of AACR Newsletters and other important announcements;
9. early notification of and reduced rates for participation in the AACR Employment Register;
10. an up-to-date Membership Directory of over 13,500 member researchers in the cancer field;
11. the professional benefits of the AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
12. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
13. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
14. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for **associate** membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all

members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<u>Receipt of Application in AACR Office</u>	<u>Notification of Candidate</u>
January 1	March
May 1	July
September 1	November

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. –OR– The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9412
E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1998 annual dues for active members are \$175, \$100 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues (\$100 in 1998) and may, if they wish, subscribe to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. optional subscriptions to the Association's high-quality journals: *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates; beginning in 1998 associate members will be able to purchase AACR journals for half the price of a regular member subscription;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. the privilege of electing an Associate Member Council that organizes programs benefiting associate members and that presents their concerns to the AACR Board of Directors;
5. the opportunity to stand for election to the Associate Member Council;
6. preferred access to the AACR Employment Register;
7. priority notification of events in the AACR's series of special conferences on timely subjects in the field;
8. substantially reduced registration rates at special conferences;
9. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
10. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
11. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the

AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues for 1998 are \$55 for associate members residing in the Americas and \$65 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1998 have been set at \$55 per year for residents of the Americas and \$65 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1998 for the forthcoming annual meeting must have paid dues for 1998. Any newly elected associate members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1998 may retain associate membership until December 31, 2002. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building · Suite 826 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483

APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____
LAST FIRST M.I. Month/Day/Year

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: _____ FAX NUMBER: _____

E-MAIL ADDRESS: _____

PRESENT ACADEMIC STATUS/TITLE (Please check only one):

____ Graduate Student ____ Medical Student
____ Physician in Training ____ Postdoctoral Fellow Gender: Male Female

PRIMARY FIELD OF RESEARCH (Please check only one):

____ Biochemistry and Biophysics ____ Biostatistics ____ Carcinogenesis
____ Cellular Biology and Genetics ____ Clinical Investigations ____ Endocrinology
____ Epidemiology ____ Immunology ____ Molecular Biology and Genetics
____ Preclinical Pharmacology and Experimental Therapeutics ____ Virology ____ Other: _____
(Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY*: _____

(Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: _____ Date: _____

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: _____ Date: _____

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. For 1998, dues are \$55 for associate members residing in the Americas and \$65 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the current forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will **not** be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR in good standing.

(This form may be reproduced.)

Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite	WordPerfect (DOS, Windows, and Macintosh)
Microsoft Word (DOS, Windows, and Macintosh)	XyWrite (DOS and Windows)

Also acceptable:

Ability	Mass 11	SoloWriter
AmiPro	MS Windows Write	Sprint
A _m S-TeX	MS Works	Stx
Appleworks	MS Works WP Mac	SunWrite
ArborTeX	Multimate	Symphony
ArborText	Multimate Advantage	TEX
ClarisWorks WP	Nibia	TeX78
CPT 8000	Nisus (to ASCII file)	Text EXecutive
CTOS	Notewriter	Textures
Diablo	Obun	Total Word
DisplayWrite	OfficeWriter	Troff
Duet	PC Write	μTeX
Einstein	PFS First Choice	Volkswriter
Enable	Professional Write	VuWriter
EXP	Q&A Write	Wang OIS
Final Word	Quark XPress	Wang WPS
FullWrite	RagTime MS Works (to ASCII file)	Wang Writer
GemWord Plus	Rich Text Format	Window Works
IBM Writing Assistant	RSG (to ASCII file)	Windows Write
Interleaf	Signature	WiziWord
LaTeX	SLiTeX	Wordstar
Latex	SmartWhere	Wordstar 2000
Leading Edge	SmartWrite II	WriteNow
Lotus Manuscript		Xerox
Lotus Write		

Software packages that we are unable to translate:

FrameMaker	Ready, Set, Go
PageMaker	Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.



DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in **one** file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide **ALL** the information.

Name used to access paper on disk: _____

Name of computer used (e.g., IBM/PS2): _____

Operating system and version (e.g., DOS 3.3): _____

Word processing program and version (e.g., WordPerfect 5.0): _____

[See reverse for acceptable programs.]

Manuscript number: _____

First author: _____

Corresponding author (if different from first author): _____

Telephone/FAX numbers: _____

Your Link to the Latest Treatment Strategies



Published by the
American Association
for Cancer Research

Clinical Cancer Research: Your source for:

- **Reports of clinical trials**
Descriptions of the latest treatment strategies being employed worldwide
- **Translational studies**
Critical research bridging the lab and the clinic
- **Minireviews**
Concise, informative summaries of broad areas of oncology
- **Meeting reports, and more**
Reports from scientific meetings, plus special lectures, letters to the editor, and more

Editor-in-Chief:

John Mendelsohn, M.D.
UT M.D. Anderson Cancer Center



SUBSCRIBE TODAY!

Call 1-800-633-4931 or (205) 995-1567 or return the coupon below.

Yes! I'd like to subscribe!

Clinical Cancer Research
Vol. 4, 1998, 12 issues, ISSN 1078-0432

AACR Members:

Contact AACR for special subscription rates

Individual (For individual use only; not for use in a library)

- \$120
- \$ 40 should be added for delivery outside the U.S.

Institutional (Available only as a combined subscription with *Cancer Research*)

- \$795
 - \$130 should be added for delivery outside the U.S.
- Canada: Add 7% GST; MD: Add State Sales Tax

Name _____

Address _____

City _____ State _____ Postal Code _____

Country _____

Method of Payment

- Enclosed check or money order in U.S. dollars drawn on U.S. bank. Payable to American Association for Cancer Research.
- Institutional purchase order # _____ is enclosed.
- Please charge my MasterCard VISA American Express

Account Name _____

Account Number _____

Expiration Date _____

Signature _____

Mail coupon to:

Clinical Cancer Research, Subscription Office,
P.O. Box 11806, Birmingham, AL 35202, USA.
If paying by credit card, fax form to: (205) 995-1588.

AMERICAN ASSOCIATION FOR CANCER RESEARCH SCIENTIFIC CONFERENCES

JUNE 14-18, 1998

Proteases and Protease Inhibitors in Cancer

Co-Sponsored by Acta Pathologica Microbiologica
Immunologica Scandinavica
Chairpersons: Keld Dano, Copenhagen, Denmark; and
Lynn M. Matrisian, Nashville, TN
Nyborg Strand Conference Center, Nyborg, Denmark

SEPTEMBER 24-28, 1998

Cellular Targets of Viral Carcinogenesis

Chairpersons: Thea D. Tlsty, San Francisco, CA,
Peter M. Howley, Boston, MA, and Eileen P. White,
Piscataway, NJ
Marriott's Laguna Cliffs Resort, Dana Point, CA

OCTOBER 14-18, 1998

***Gene Regulation and Cancer (10th Anniversary
of the AACR Special Conferences)***

Chairpersons: Phillip A. Sharp, Cambridge, MA,
Jacqueline A. Lees, Cambridge, MA, and Steven L.
McKnight, Dallas, TX
The Homestead, Hot Springs, VA

NOVEMBER 11-15, 1998

Endogenous Sources of Mutations

Chairpersons: Lawrence J. Marnett, Nashville, TN;
James A. Swenberg, Chapel Hill, NC; Tomas A.
Lindahl, Herts, England
Sanibel Harbour Resort and Spa, Ft. Myers, FL



DECEMBER 2-6, 1998

***New Research Approaches to the Prevention
and Cure of Prostate Cancer***

Chairpersons: Jonathan W. Simons, Baltimore, MD,
and Kenneth J. Pienta, Ann Arbor, MI
Hyatt Grand Champions Resort, Indian Wells (Palm
Springs), CA

JANUARY 8-12, 1999

The Steroid Receptor Superfamily

Chairpersons: M. Geoffrey Rosenfeld, La Jolla, CA;
Additional Chairperson to be Announced
Renaissance Esmeralda Resort, Indian Wells (Palm
Springs), CA

JANUARY 31-FEBRUARY 5, 1999

***Cancer Biology and the Mutant Mouse: New
Methods, New Models, New Insights***

Chairpersons: Tyler Jacks, Cambridge, MA; Ronald A.
DePinho, New York, NY
Keystone Resort, Keystone, CO

APRIL 10-14, 1999

90th Annual Meeting

Chairperson: Waun Ki Hong, Houston, TX;
Co-Chairpersons: Carol W. Greider, Cold Spring
Harbor, NY, Leroy F. Liu, Piscataway, NJ, and Josep
F. Fraumeni, Jr., Bethesda, MD
Pennsylvania Convention Center, Philadelphia, PA
Abstract Deadline: November 6, 1998

AACR members will receive brochures on the
above conferences as soon as they are available.
Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: meetings@aacr.org
*For regular updates to this list visit the AACR's
Website, <http://www.aacr.org>*